Category Archives: HIV care & treatment

Project Inform staff Emalie Huriaux’s whirlwind of advocacy


In FY 15-16 CalHEP and Project Inform successfully advocated for state funding for the California Department of Public Health to establish a syringe supply clearinghouse to support HIV and viral hepatitis prevention services around the state. Here is CalHEP Chair, Emalie Huriaux, with some of the supplies from…Read More

Generic HIV drugs will be a good thing right?

In 2017, the patents for two antiretroviral drugs for HIV that continue to be widely used will  likely expire in the United States and generic alternatives at lower market prices could be introduced. Some have long awaited this occurrence, hoping for increased competition and a drive…Read More

Ensuring Access to Medi-Cal Services for Transgender Beneficiaries


On October 6, 2016, California’s Department of Health Care Services issued the following letter and resources regarding transgender health care coverage under Medi-Cal plans. The APL (All Plan Letter) is available by clicking this link. The website link for all letters is available by clicking this…Read More

AIDS2016: No HIV transmission events from condomless sex between mixed-HIV-status couples


The European PARTNER study is now the second large HIV study to determine that full viral suppression due to antiretroviral therapy renders an HIV-positive person nearly completely uninfectious to their HIV-negative sex partners. The study was published in JAMA prior to the AIDS 2016 conference in…Read More

AIDS2016: Switching to single pill regimen controls HIV as well as other standard treatment


New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single tablet regimen of Triumeq (dolutegravir + abacavir + lamivudine). The STRIIVING study presented 48-week data on switching to Triumeq from various other regimens in people currently on treatment…Read More

AIDS2016: Long-acting injectable two-drug HIV regimen works well as oral “maintenance” treatment


People who switched to a new long-acting two-drug injectable HIV regimen after a lead-in period of oral treatment showed equal control of the virus as those who stayed on the oral regimen. The LATTE-2 study presented early data that showed that long acting formulations of the…Read More

AIDS2016: Most study participants were satisfied with a new long-acting injectable HIV regimen


A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma. An analysis was presented from 39 in-depth interviews of 27 participants (2 of whom were women) and 12 clinicians…Read More